<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>July</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1613-0073</issn>
    </journal-meta>
    <article-meta>
      <title-group>
        <article-title>Bridging Structural and Functional Imaging: Integrated PET/CT Radiomics with Explainable Machine Learning</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <string-name>Pierfrancesco Novielli</string-name>
          <email>pierfrancesco.novielli@uniba.it</email>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Donato Romano</string-name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Michele Magarelli</string-name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Pierpaolo Di Bitonto</string-name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Roberto Bellotti</string-name>
          <xref ref-type="aff" rid="aff0">0</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Sabina Tangaro</string-name>
          <email>sabina.tangaro@uniba.it</email>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Workshop</string-name>
        </contrib>
        <contrib contrib-type="editor">
          <string-name>Explainable AI, SHAP, Radiomics, PET-CT Imaging, Lung Cancer Classification, Machine Learning</string-name>
        </contrib>
        <aff id="aff0">
          <label>0</label>
          <institution>Dipartimento Interateneo di Fisica ”M. Merlin”, Università degli Studi di Bari Aldo Moro</institution>
          ,
          <addr-line>Bari</addr-line>
          ,
          <country country="IT">Italy</country>
        </aff>
        <aff id="aff1">
          <label>1</label>
          <institution>Dipartimento di Scienze del Suolo, della Pianta e degli Alimenti, Università degli Studi di Bari Aldo Moro</institution>
          ,
          <addr-line>Bari</addr-line>
          ,
          <country country="IT">Italy</country>
        </aff>
        <aff id="aff2">
          <label>2</label>
          <institution>Istituto Nazionale di Fisica Nucleare, Sezione di Bari</institution>
          ,
          <addr-line>Bari</addr-line>
          ,
          <country country="IT">Italy</country>
        </aff>
      </contrib-group>
      <pub-date>
        <year>2025</year>
      </pub-date>
      <volume>0</volume>
      <fpage>9</fpage>
      <lpage>11</lpage>
      <abstract>
        <p>This work presents a radiomic-based framework for the classification of metastatic versus non-metastatic lung lesions using multimodal imaging features from PET and CT scans. The proposed pipeline integrates Extreme Gradient Boosting (XGBoost) with SHapley Additive exPlanations (SHAP) to enhance model interpretability. A comparative evaluation shows that the fusion of PET and CT radiomics improves classification performance compared to unimodal analysis. SHAP values provide insights into feature importance, highlighting the complementary roles of structural and metabolic imaging. This Late-Breaking Work addresses key challenges in explainability, reproducibility, and clinical relevance, contributing toward trustworthy AI in medical imaging.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="sec-1">
      <title>-</title>
      <p>PET/CT</p>
    </sec>
    <sec id="sec-2">
      <title>1. Introduction</title>
      <p>Lung cancer and metastatic pulmonary lesions represent a persistent challenge in clinical oncology.
Accurate and early diagnosis is essential to guide treatment strategies and improve patient survival</p>
      <p>CEUR</p>
      <p>ceur-ws.org
distinct information, PET may produce false positives due to inflammatory uptake, and CT findings can
be non-specific. In this context, the integration of radiomic features extracted from both PET and CT
scans allows for a more comprehensive characterization of lesion properties. Such structural-functional
fusion has shown promise in improving diagnostic accuracy, particularly in oncologic applications [9].</p>
      <p>In this work, we present a machine learning-based framework that combines radiomic features
from PET, CT, and PET-CT images to classify lung lesions as metastatic or non-metastatic. We use
eXtreme Gradient Boosting (XGBoost) for its eficiency and strong performance on structured data
[10]. Radiomic features extracted from each imaging modality include intensity metrics (e.g., SUVmin,
SUVmean), shape descriptors, and texture-based features such as those derived from the Gray-Level
Co-occurrence Matrix (GLCM).</p>
      <p>A key objective of this study is to address the issue of model interpretability. While ML models
can achieve high accuracy, their clinical adoption is limited if predictions are not explainable. To
this end, we integrate Explainable Artificial Intelligence (XAI) into our workflow, specifically through
SHapley Additive exPlanations (SHAP) [11]. SHAP assigns importance values to each feature based on
its contribution to the model output, ofering both global and patient-specific interpretability [ 12, 13].</p>
      <p>The main contributions of this study are:
• A comparative analysis of radiomic features derived from CT, PET, and their integration through
feature-level fusion.
• The use of SHAP to identify and visualize the most influential features contributing to lesion
classification.
• A transparent and reproducible pipeline that combines predictive accuracy with clinical
interpretability.</p>
      <p>By bridging radiomics, machine learning, and explainability, this work contributes to the development
of reliable AI tools for lung cancer diagnosis. The proposed framework supports not only performance
benchmarking across modalities but also delivers insights into feature relevance, reinforcing clinical
trust and interpretability in AI-based imaging solutions.</p>
    </sec>
    <sec id="sec-3">
      <title>2. Related Work</title>
      <p>Radiomics has emerged as a powerful approach for quantifying imaging biomarkers, with early landmark
studies such as Aerts et al. [14] demonstrating its utility in predicting prognosis in lung cancer using
CTbased features. Subsequent works extended radiomic analysis to PET and PET-CT imaging, highlighting
the potential of metabolic features for tumor characterization [9, 15].</p>
      <p>Several studies have explored the predictive power of radiomics in distinguishing benign from
malignant lung lesions [16, 17]. However, most models have prioritized performance over interpretability,
limiting their clinical applicability.</p>
      <p>Explainable AI techniques, such as SHAP, have recently gained attention in the biomedical domain,
ofering insights into feature contributions at both global and local levels. Compared to other XAI
methods like LIME or Grad-CAM, SHAP is particularly well-suited for tabular radiomic data thanks
to its stability, local consistency, and its solid mathematical foundation based on cooperative game
theory [11].</p>
      <p>Radiomic features are typically structured, high-dimensional, and exhibit complex correlations,
making SHAP’s local accuracy and ability to model feature interactions particularly valuable for
deriving reliable and clinically meaningful interpretations[18].</p>
      <p>While some recent works have applied SHAP to CT or PET-based radiomic classifiers [ 19], few have
systematically investigated its application to multimodal PET-CT fusion. To the best of our knowledge,
this is among the first studies to combine PET and CT radiomic features with SHAP-based interpretation
for metastatic lung lesion classification, ofering a transparent and reproducible pipeline that balances
performance and explainability.</p>
    </sec>
    <sec id="sec-4">
      <title>3. Materials and Methods</title>
      <sec id="sec-4-1">
        <title>3.1. Dataset Description</title>
        <p>This study employs a publicly available dataset from Kirienko et al. [9], which includes patients who
underwent FDG PET/CT scans for the evaluation of lung lesions between 2011 and 2017. Eligibility
criteria required patients to be over 18 years old and to have a histologically confirmed diagnosis of
either primary or metastatic lung tumors.</p>
        <p>Importantly, the dataset is already provided in a structured format containing radiomic features that
were pre-extracted using the LIFEx software package from semiautomatically segmented PET and CT
images [20]. Clinical metadata such as age, sex, and histological subtype were also available. Further
demographic details are reported in the original publication.</p>
      </sec>
      <sec id="sec-4-2">
        <title>3.2. Data Preparation</title>
        <p>For this analysis, we selected the 468 patients who underwent both PET and CT imaging. Among them,
105 were diagnosed with metastatic lesions and 363 with non-metastatic lesions. Radiomic features
were extracted from segmented lung lesions using standardized protocols, generating three datasets:
• CT-only: 41 radiomic features.
• PET-only: 43 radiomic features.</p>
        <p>• PET+CT: 84 combined features.</p>
      </sec>
      <sec id="sec-4-3">
        <title>3.3. Addressing Class Imbalance</title>
        <p>The dataset was afected by a pronounced class imbalance. To mitigate this, we applied random
undersampling of the majority class (non-metastatic), generating balanced subsets of 105 vs. 105
samples. This process was repeated 100 times with diferent random seeds to ensure coverage and
reduce sampling bias. We also experimented with SMOTE, but it resulted in lower performance and
increased overfitting. Hence, undersampling was adopted for its better generalization performance in
cross-validation [21].</p>
      </sec>
      <sec id="sec-4-4">
        <title>3.4. Machine Learning Approach</title>
        <p>Our classification pipeline is outlined in Figure 1. The XGBoost algorithm was chosen after a comparative
evaluation against Random Forest, Support Vector Machines (SVM), and Logistic Regression. Across all
datasets, XGBoost consistently achieved the highest AUROC and F1-score. Furthermore, its compatibility
with SHAP makes it particularly suitable for interpretable radiomic applications [10].</p>
        <p>Each model was trained using 10-fold cross-validation, repeated 100 times to ensure robustness.
Evaluation metrics included F1-score, Accuracy, Specificity, Precision, Sensitivity, Area Under the ROC
Curve (AUROC), and Area Under the Precision-Recall Curve (AUPRC).</p>
      </sec>
      <sec id="sec-4-5">
        <title>3.5. Explainable AI with SHAP</title>
        <p>To interpret model predictions, we employed SHapley Additive exPlanations (SHAP), a game-theoretic
approach that assigns each feature a contribution score for every prediction [11]. SHAP values were
computed for all models and used to analyze feature importance both globally and locally.</p>
        <p>
          The SHAP value for a feature  in a sample  is defined as:
Φ () =
∑
 ⊆−
| |!(|| − | | − 1)!
||!
[  ( ∪ ) −   ( )]
(
          <xref ref-type="bibr" rid="ref1">1</xref>
          )
        </p>
        <p>This enables the identification of radiomic traits most responsible for distinguishing between
metastatic and non-metastatic lesions, ofering actionable insights to clinicians and radiologists.</p>
      </sec>
    </sec>
    <sec id="sec-5">
      <title>4. Results</title>
      <p>This study evaluated the efectiveness of radiomic features extracted from CT, PET, and the integration
of features from both modalities in classifying metastatic versus non-metastatic lung lesions using the
XGBoost classifier. Results demonstrated that PET-derived features provided higher discriminative
power compared to CT features alone, and the integration of features from both modalities yielded the
best performance.</p>
      <sec id="sec-5-1">
        <title>4.1. Classification Performance</title>
        <p>The model was evaluated using a repeated 10-fold cross-validation strategy. Classification metrics,
including Accuracy, F1-score, Precision, Sensitivity, Specificity, AUROC, and AUPRC, were averaged
over 100 repetitions (Table 1). PET-based features achieved the highest standalone performance (AUROC:
0.863±0.053), while combining PET and CT features further improved accuracy and robustness (AUROC:
0.887 ± 0.048).</p>
        <p>Metric
F1 Score
Accuracy
Specificity
Precision
Sensitivity
AUROC
AUPRC</p>
        <p>CT
0.679 ± 0.068
0.674 ± 0.063
0.655 ± 0.090
0.670 ± 0.064
0.694 ± 0.098
0.728 ± 0.067
0.707 ± 0.080</p>
        <p>PET
0.802 ± 0.052
0.797 ± 0.053
0.767 ± 0.085
0.785 ± 0.062
0.827 ± 0.079
0.863 ± 0.053
0.825 ± 0.076</p>
        <p>PET-CT
0.828 ± 0.054
0.824 ± 0.054
0.798 ± 0.078
0.811 ± 0.062
0.850 ± 0.078
0.887 ± 0.048
0.865 ± 0.067</p>
      </sec>
      <sec id="sec-5-2">
        <title>4.2. Explainability with SHAP</title>
        <p>To provide interpretability to the model’s decisions, SHAP (SHapley Additive exPlanations) analysis
was performed for each imaging modality. SHAP summary plots visualize both the importance of
individual features and the direction of their influence on predictions. In each plot, features are ranked
by their overall contribution to the model’s output. Each dot represents a patient; its color reflects the
actual feature value (red = high, blue = low), and its horizontal position indicates the SHAP value—i.e.,
how much that feature increases (right) or decreases (left) the probability of predicting a metastasis.</p>
        <p>Figure 2 presents the SHAP summary plots for the CT, PET, and PET–CT feature integration datasets,
highlighting both modality-specific predictors and complementary features contributing to metastasis
classification.</p>
        <p>(a) CT-based radiomics features
(b) PET-based radiomics features
(c) Structural-functional radiomic feature integration</p>
        <p>(CT + PET)
CT-based radiomics features. In the CT dataset, texture and intensity-based features were the
primary contributors. Long Run Emphasis (LRE_GLRLM_CT) and High-Order Energy (EnergyH_CT)
exhibited a negative association with metastasis probability, suggesting that metastatic lesions tend to
be more heterogeneous and have a less uniform intensity distribution. Additionally, shape descriptors
such as Compacity_CT contributed to capturing geometric variability between lesion types.
PET-based radiomics features. Metabolic and texture-related PET features strongly influenced
model predictions. SUVmin_PET emerged as the most influential feature and, interestingly, exhibited
a negative correlation with metastasis, suggesting that some metastatic lesions may present lower
focal uptake. SUVmean_PET and Correlation_GLCM_PET also emerged as key features, highlighting
complex uptake patterns and spatial relationships indicative of malignancy.</p>
        <p>Integrated CT-PET features. The integration of PET and CT features enabled complementary
information fusion. SUVmin_PET remained the most influential predictor, reinforcing its discriminative
value. Features such as LZHGE_GLZLM_PET (Large Zone High Gray-Level Emphasis) captured
additional textural complexity in metastatic lesions, while EnergyH_CT contributed morphological
information, confirming the benefit of multimodal radiomic fusion in enhancing model explainability
and performance.</p>
      </sec>
    </sec>
    <sec id="sec-6">
      <title>5. Discussion</title>
      <p>This study highlights the potential of radiomic features extracted from PET and CT imaging for the
non-invasive classification of lung lesions as metastatic or non-metastatic. PET-derived metabolic
features, such as SUVmin and SUVmean, were among the most discriminative. Interestingly, SUVmin
was negatively correlated with metastasis, suggesting that certain metastatic lesions may exhibit lower
metabolic activity. This finding may reflect underlying biological factors, such as tumor heterogeneity
or microenvironmental efects, and supports previous work emphasizing the complex behavior of
radiomic biomarkers [22].</p>
      <p>Texture-based features, particularly those derived from Gray-Level Co-occurrence Matrix (GLCM)
and Gray-Level Zone Length Matrix (GLZLM), also showed strong associations with metastatic status.
Metrics such as Correlation_GLCM_PET, Contrast_GLCM_CT, and LZHGE_GLZLM_PET indicated greater
heterogeneity in metastatic lesions, consistent with prior findings on texture complexity in malignant
tissues [23].</p>
      <p>Multimodal integration of PET and CT features significantly improved classification performance
over single-modality models. PET provided insights into metabolic activity, while CT added valuable
information about lesion morphology and signal distribution. The complementary nature of these
modalities reinforces the growing interest in multi-parametric imaging for precision oncology [24].</p>
      <p>Importantly, SHAP-based analysis enabled interpretable model outputs, identifying the most
influential features and their direction of impact on classification. This enhances transparency, which is a
critical factor for clinical adoption of AI tools [25]. By highlighting feature contributions on a per-sample
basis, SHAP promotes model trustworthiness and facilitates integration into decision-support systems.</p>
      <p>Despite these promising results, several limitations should be acknowledged. The dataset, though
carefully curated, is relatively small, which may afect generalizability. Although class imbalance was
addressed via repeated random undersampling, alternative approaches such as class-weighted loss
functions could be considered in future work to further mitigate bias. Moreover, some features that were
predictive in the unimodal CT or PET settings became less relevant when combined, suggesting possible
redundancy or dominance efects in the fused feature space—an aspect that deserves deeper exploration,
potentially with the aid of domain knowledge. Finally, while SHAP provided interpretable insights, its
limitations—particularly in the presence of highly correlated features—should not be overlooked [26].
Alternative or complementary XAI methods, such as counterfactuals or interaction-aware attributions,
may help further refine the interpretability and clinical utility of radiomic models.</p>
    </sec>
    <sec id="sec-7">
      <title>6. Conclusions</title>
      <p>This work presents a preliminary investigation into the use of radiomic features extracted from PET and
CT imaging for classifying lung lesions as metastatic or non-metastatic. The integration of metabolic
and structural descriptors allowed for a more comprehensive characterization of lesion properties,
ofering insights into how tumor biology afects both tissue morphology and metabolic behavior. While
the combination of features did not yield a drastic performance gain over PET alone, it provided a richer
and more interpretable representation of disease traits.</p>
      <p>The use of XGBoost, paired with SHAP-based explanations, enabled transparent feature attribution
and highlighted complementary roles of CT and PET-derived metrics. These insights could support a
better understanding of disease patterns and assist clinicians in identifying key imaging phenotypes
associated with metastatic progression.</p>
      <p>Although the findings are promising, this study represents an early step toward clinically applicable
radiomic decision support. Future work will explore deep learning models capable of learning complex
feature hierarchies directly from imaging data, as well as more advanced explainability tools. In
particular, the use of SHAP interaction values may reveal synergistic relationships between features,
shedding light on how structural and metabolic traits jointly influence classification.</p>
      <p>Validation on external, multi-institutional cohorts will be critical to assess generalizability. Ultimately,
interpretable and biologically informed AI frameworks have the potential to enhance diagnostic accuracy
and support precision oncology workflows in lung cancer care.</p>
    </sec>
    <sec id="sec-8">
      <title>Acknowledgments</title>
      <p>Authors would like to thank the resources made available by ReCaS, a project funded by the MIUR (Italian
Ministry for Education, University and Research) in the “PON Ricerca e Competitività 2007–2013-Azione
I-Interventi di raforzamento strutturale” PONa3_00052, Avviso 254/Ric, University of Bari.</p>
    </sec>
    <sec id="sec-9">
      <title>Declaration on Generative AI</title>
      <p>During the preparation of this work, the authors used OpenAI’s GPT-4 (ChatGPT) exclusively for
grammar and spelling checks. After using these tool(s)/service(s), the author(s) reviewed and edited the
content as needed and take(s) full responsibility for the publication’s content.
[8] D. L. Bailey, M. N. Maisey, D. W. Townsend, P. E. Valk, Positron emission tomography, volume 2,</p>
      <p>Springer, 2005.
[9] M. Kirienko, L. Cozzi, A. Rossi, E. Voulaz, L. Antunovic, A. Fogliata, A. Chiti, M. Sollini, Ability of
fdg pet and ct radiomics features to diferentiate between primary and metastatic lung lesions,
European journal of nuclear medicine and molecular imaging 45 (2018) 1649–1660.
[10] T. Chen, C. Guestrin, Xgboost: A scalable tree boosting system, in: Proceedings of the 22nd acm
sigkdd international conference on knowledge discovery and data mining, 2016, pp. 785–794.
[11] S. Lundberg, A unified approach to interpreting model predictions, arXiv preprint arXiv:1705.07874
(2017).
[12] P. Novielli, D. Romano, M. Magarelli, D. Diacono, A. Monaco, N. Amoroso, M. Vacca, M. De Angelis,
R. Bellotti, S. Tangaro, Personalized identification of autism-related bacteria in the gut microbiome
using explainable artificial intelligence, Iscience 27 (2024).
[13] P. Novielli, M. Magarelli, D. Romano, L. de Trizio, P. Di Bitonto, A. Monaco, N. Amoroso, A. M.</p>
      <p>Stellacci, C. Zoani, R. Bellotti, et al., Climate change and soil health: Explainable artificial
intelligence reveals microbiome response to warming, Machine Learning and Knowledge Extraction 6
(2024) 1564–1578.
[14] H. J. Aerts, E. R. Velazquez, R. T. Leijenaar, C. Parmar, P. Grossmann, S. Carvalho, J. Bussink,
R. Monshouwer, B. Haibe-Kains, D. Rietveld, et al., Decoding tumour phenotype by noninvasive
imaging using a quantitative radiomics approach, Nature communications 5 (2014) 4006.
[15] S. Ha, H. Choi, J. C. Paeng, G. J. Cheon, Radiomics in oncological pet/ct: a methodological overview,</p>
      <p>Nuclear medicine and molecular imaging 53 (2019) 14–29.
[16] Y. Zheng, D. Zhou, H. Liu, M. Wen, Ct-based radiomics analysis of diferent machine learning
models for diferentiating benign and malignant parotid tumors, European radiology 32 (2022)
6953–6964.
[17] M. P. Starmans, R. L. Miclea, S. R. Van Der Voort, W. J. Niessen, M. G. Thomeer, S. Klein,
Classification of malignant and benign liver tumors using a radiomics approach, in: Medical Imaging
2018: Image Processing, volume 10574, SPIE, 2018, pp. 343–349.
[18] Y. Wang, J. Lang, J. Z. Zuo, Y. Dong, Z. Hu, X. Xu, Y. Zhang, Q. Wang, L. Yang, S. T. Wong, et al., The
radiomic-clinical model using the shap method for assessing the treatment response of whole-brain
radiotherapy: a multicentric study, European Radiology 32 (2022) 8737–8747.
[19] F. Duan, M. Zhang, C. Yang, X. Wang, D. Wang, Non-invasive prediction of lymph node
metastasis in nsclc using clinical, radiomics, and deep learning features from 18f-fdg pet/ct based on
interpretable machine learning, Academic Radiology 32 (2025) 1645–1655.
[20] C. Nioche, F. Orlhac, S. Boughdad, S. Reuzé, J. Goya-Outi, C. Robert, C. Pellot-Barakat, M. Soussan,
F. Frouin, I. Buvat, Lifex: a freeware for radiomic feature calculation in multimodality imaging
to accelerate advances in the characterization of tumor heterogeneity, Cancer research 78 (2018)
4786–4789.
[21] N. Qazi, K. Raza, Efect of feature selection, smote and under sampling on class imbalance
classification, in: 2012 UKSim 14th international conference on computer modelling and simulation,
IEEE, 2012, pp. 145–150.
[22] L. Pan, P. Gu, G. Huang, H. Xue, S. Wu, Prognostic significance of suv on pet/ct in patients with
esophageal cancer: a systematic review and meta-analysis, European journal of gastroenterology
&amp; hepatology 21 (2009) 1008–1015.
[23] Z. Wang, A. Zheng, Y. Li, W. Dong, X. Liu, W. Yuan, F. Gao, X. Duan, 18f-psma-1007 pet/ct
performance on risk stratification discrimination and distant metastases prediction in newly
diagnosed prostate cancer, Frontiers in Oncology 11 (2021) 759053.
[24] S. R. Cherry, Multimodality imaging: Beyond pet/ct and spect/ct, in: Seminars in nuclear medicine,
volume 39, Elsevier, 2009, pp. 348–353.
[25] A. Ghosh, D. Kandasamy, Interpretable artificial intelligence: why and when, American Journal of</p>
      <p>Roentgenology 214 (2020) 1137–1138.
[26] D. Fryer, I. Strümke, H. Nguyen, Shapley values for feature selection: The good, the bad, and the
axioms, Ieee Access 9 (2021) 144352–144360.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <mixed-citation>
          [1]
          <string-name>
            <given-names>S. J.</given-names>
            <surname>Adams</surname>
          </string-name>
          ,
          <string-name>
            <given-names>E.</given-names>
            <surname>Stone</surname>
          </string-name>
          ,
          <string-name>
            <given-names>D. R.</given-names>
            <surname>Baldwin</surname>
          </string-name>
          ,
          <string-name>
            <given-names>R.</given-names>
            <surname>Vliegenthart</surname>
          </string-name>
          ,
          <string-name>
            <given-names>P.</given-names>
            <surname>Lee</surname>
          </string-name>
          ,
          <string-name>
            <given-names>F. J.</given-names>
            <surname>Fintelmann</surname>
          </string-name>
          , Lung cancer screening,
          <source>The Lancet</source>
          <volume>401</volume>
          (
          <year>2023</year>
          )
          <fpage>390</fpage>
          -
          <lpage>408</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref2">
        <mixed-citation>
          [2]
          <string-name>
            <given-names>A. A.</given-names>
            <surname>Ardakani</surname>
          </string-name>
          ,
          <string-name>
            <given-names>N. J.</given-names>
            <surname>Bureau</surname>
          </string-name>
          ,
          <string-name>
            <given-names>E. J.</given-names>
            <surname>Ciaccio</surname>
          </string-name>
          ,
          <string-name>
            <given-names>U. R.</given-names>
            <surname>Acharya</surname>
          </string-name>
          ,
          <article-title>Interpretation of radiomics features-a pictorial review</article-title>
          ,
          <source>Computer methods and programs in biomedicine 215</source>
          (
          <year>2022</year>
          )
          <fpage>106609</fpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref3">
        <mixed-citation>
          [3]
          <string-name>
            <given-names>H. T.</given-names>
            <surname>Winer-Muram</surname>
          </string-name>
          ,
          <article-title>The solitary pulmonary nodule</article-title>
          ,
          <source>Radiology</source>
          <volume>239</volume>
          (
          <year>2006</year>
          )
          <fpage>34</fpage>
          -
          <lpage>49</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref4">
        <mixed-citation>
          [4]
          <string-name>
            <given-names>A.</given-names>
            <surname>Câmara-de Souza</surname>
          </string-name>
          ,
          <string-name>
            <given-names>M.</given-names>
            <surname>Toyoshima</surname>
          </string-name>
          ,
          <string-name>
            <given-names>M.</given-names>
            <surname>Giannella</surname>
          </string-name>
          ,
          <string-name>
            <given-names>D.</given-names>
            <surname>Freire</surname>
          </string-name>
          ,
          <string-name>
            <given-names>C.</given-names>
            <surname>Camacho</surname>
          </string-name>
          ,
          <string-name>
            <given-names>D. Lourenço</given-names>
            <surname>Jr</surname>
          </string-name>
          ,
          <string-name>
            <given-names>M.</given-names>
            <surname>Rocha</surname>
          </string-name>
          ,
          <string-name>
            <given-names>T.</given-names>
            <surname>Bacchella</surname>
          </string-name>
          ,
          <string-name>
            <given-names>R.</given-names>
            <surname>Jureidini</surname>
          </string-name>
          ,
          <string-name>
            <given-names>M.</given-names>
            <surname>Machado</surname>
          </string-name>
          , et al.,
          <article-title>Insulinoma: A retrospective study analyzing the diferences between benign and malignant tumors</article-title>
          ,
          <source>Pancreatology</source>
          <volume>18</volume>
          (
          <year>2018</year>
          )
          <fpage>298</fpage>
          -
          <lpage>303</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref5">
        <mixed-citation>
          [5]
          <string-name>
            <given-names>S. H.</given-names>
            <surname>Bradley</surname>
          </string-name>
          ,
          <string-name>
            <given-names>B. S.</given-names>
            <surname>Bhartia</surname>
          </string-name>
          ,
          <string-name>
            <given-names>M. E.</given-names>
            <surname>Callister</surname>
          </string-name>
          ,
          <string-name>
            <given-names>W. T.</given-names>
            <surname>Hamilton</surname>
          </string-name>
          ,
          <string-name>
            <given-names>N. L. F.</given-names>
            <surname>Hatton</surname>
          </string-name>
          ,
          <string-name>
            <given-names>M. P.</given-names>
            <surname>Kennedy</surname>
          </string-name>
          ,
          <string-name>
            <given-names>L. T.</given-names>
            <surname>Mounce</surname>
          </string-name>
          ,
          <string-name>
            <given-names>B.</given-names>
            <surname>Shinkins</surname>
          </string-name>
          ,
          <string-name>
            <given-names>P.</given-names>
            <surname>Wheatstone</surname>
          </string-name>
          ,
          <string-name>
            <given-names>R. D.</given-names>
            <surname>Neal</surname>
          </string-name>
          ,
          <article-title>Chest x-ray sensitivity and lung cancer outcomes: a retrospective observational study</article-title>
          ,
          <source>British Journal of General Practice</source>
          <volume>71</volume>
          (
          <year>2021</year>
          )
          <fpage>e862</fpage>
          -
          <lpage>e868</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref6">
        <mixed-citation>
          [6]
          <string-name>
            <surname>K. M. Latimer</surname>
            ,
            <given-names>T. F.</given-names>
          </string-name>
          <string-name>
            <surname>Mott</surname>
          </string-name>
          ,
          <article-title>Lung cancer: diagnosis, treatment principles</article-title>
          , and screening,
          <source>American family physician 91</source>
          (
          <year>2015</year>
          )
          <fpage>250</fpage>
          -
          <lpage>256</lpage>
          .
        </mixed-citation>
      </ref>
      <ref id="ref7">
        <mixed-citation>
          [7]
          <string-name>
            <given-names>T. M.</given-names>
            <surname>Buzug</surname>
          </string-name>
          ,
          <article-title>Computed tomography</article-title>
          , in: Springer handbook of medical technology, Springer,
          <year>2011</year>
          , pp.
          <fpage>311</fpage>
          -
          <lpage>342</lpage>
          .
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>